Squarepoint Ops LLC decreased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 29.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,559 shares of the company's stock after selling 3,947 shares during the period. Squarepoint Ops LLC's holdings in Krystal Biotech were worth $1,498,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of the business. FMR LLC grew its position in shares of Krystal Biotech by 0.5% in the fourth quarter. FMR LLC now owns 4,314,014 shares of the company's stock valued at $675,833,000 after purchasing an additional 21,133 shares in the last quarter. Vanguard Group Inc. lifted its position in Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock worth $450,938,000 after buying an additional 28,707 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in Krystal Biotech by 0.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock worth $411,831,000 after buying an additional 6,600 shares during the last quarter. Hood River Capital Management LLC grew its holdings in Krystal Biotech by 2.1% in the 4th quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after buying an additional 10,622 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Krystal Biotech by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after acquiring an additional 71,200 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.
Insider Buying and Selling at Krystal Biotech
In related news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This represents a 1.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.70% of the stock is currently owned by corporate insiders.
Krystal Biotech Price Performance
Shares of NASDAQ:KRYS traded up $1.12 during mid-day trading on Wednesday, reaching $132.03. 234,692 shares of the company were exchanged, compared to its average volume of 311,039. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $219.34. The firm's 50-day simple moving average is $151.55 and its 200 day simple moving average is $163.81. The firm has a market cap of $3.82 billion, a price-to-earnings ratio of 44.16 and a beta of 0.79.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. On average, research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on KRYS. Guggenheim lowered their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Chardan Capital reiterated a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a report on Wednesday, May 7th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Citigroup lowered their price objective on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research report on Friday, May 16th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech currently has a consensus rating of "Buy" and an average price target of $211.13.
Check Out Our Latest Stock Analysis on KRYS
About Krystal Biotech
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
See Also
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
